Skip to main content

Multisystem Cell Therapy for Improvement of Urinary Continence

Objective

"Stress Urinary Incontinence (SUI) is a disease affecting over 200 million people worldwide. It represents a condition with a prevalence of 20-50% in women, thereby creating an immense socio-economic burden. The currently available treatment strategies entail various complications and offer only short-term relief to the patients. Tissue engineering using autologous cells offers a feasible alternative for functional restoration of the damaged urinary sphincter muscle and represents an ideal treatment option that could reverse the underlying pathologic conditions.
MUSIC aims at translating basic knowledge on regenerative medicine (RM) and stem cell therapy into the clinic by undertaking a ""first-in-man"" multisystem study using autologous muscle precursor cells (MPCs) in a combination with neuromuscular electromagnetic stimulation (NMES) in 40 female patients. We will carry out the specific tasks to prove safety and efficacy of the proposed novel multilevel treatment as well as reproducibility of the therapeutic effect. Additional objectives are optimization of the advanced-therapy medicinal product (ATMP) towards totally xeno-free and facilitated manufacturing as well as the introduction of a novel injection technique for more efficient and precise implantation of the final product.
Combining expertise, MUSIC features a unique infrastructure, including the knowledge of experts in the fields of RM, urology, cellular biology and biomaterials throughout Europe (CH, NL, UK, A, D). The MUSIC consortium has an exclusive opportunity to determine the validity of this MPC cellular treatment in combination with NMES and to further improve its feasibility and clinical efficacy. The ultimate goal is to significantly improve the patients` quality of life and to exploit a future commercial opportunity by expanding the know-how to various smaller RM centers and companies within Europe, thus, making personalized medicine using autologous cells a more feasible SUI treatment option.


"

Call for proposal

H2020-SC1-2016-2017

See other projects for this call

Sub call

H2020-SC1-2016-RTD

Coordinator

UNIVERSITAT ZURICH
Net EU contribution
€ 0,00
Address
Ramistrasse 71
8006 Zurich
Switzerland

See on map

Region
Schweiz/Suisse/Svizzera Zürich Zürich
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00

Participants (6)

KUROS BIOSCIENCES BV

Participation ended

Netherlands
Net EU contribution
€ 0,00
Address
Professor Bronkhorstlaan 10 G 48
3723 MB Bilthoven
SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
West-Nederland Utrecht Utrecht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00
COLLAGEN SOLUTIONS (UK) LIMITED
United Kingdom
Net EU contribution
€ 562 197,50
Address
3 Robroyston Oval Nova Business Park
G33 1AP Glasgow

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
West Central Scotland Glasgow City
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 562 197,50
PARACELSUS MEDIZINISCHE PRIVATUNIVERSITAT SALZBURG - PRIVATSTIFTUNG
Austria
Net EU contribution
€ 187 500,00
Address
Strubergasse 21
5020 Salzburg

See on map

Region
Westösterreich Salzburg Salzburg und Umgebung
Activity type
Higher or Secondary Education Establishments
Other funding
€ 187 500,00
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Germany
Net EU contribution
€ 575 223,75
Address
Geschwister-scholl-platz
72074 Tuebingen

See on map

Region
Baden-Württemberg Tübingen Tübingen, Landkreis
Activity type
Higher or Secondary Education Establishments
Other funding
€ 575 223,75
SCINUS HOLDING BV

Participation ended

Netherlands
Net EU contribution
€ 997 771,00
Address
Professor Bronkhorstlaan 10 G 48
3723 MB Bilthoven
SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
West-Nederland Utrecht Utrecht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 997 771,00
SCINUS CELL EXPANSION NETHERLANDS B.V.
Netherlands
Net EU contribution
€ 26 829,00
Address
Professor Bronkhorstlaan 10, Building 48
3723 MB Bilthoven

See on map

Region
West-Nederland Utrecht Utrecht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 26 829,00